{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:20:17Z","timestamp":1793661617411,"version":"4.5.1"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T00:00:00Z","timestamp":1499385600000},"content-version":"am","delay-in-days":340,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006229","name":"Oak Ridge Institute for Science and Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006229","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.cbi.2015.10.009","type":"journal-article","created":{"date-parts":[[2015,10,25]],"date-time":"2015-10-25T11:48:07Z","timestamp":1445773687000},"page":"63-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"special_numbering":"C","title":["Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity"],"prefix":"10.1016","volume":"255","author":[{"given":"Jiekun","family":"Xuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baitang","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Tolleson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2015.10.009_bib1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd1750","article-title":"Idiosyncratic drug hepatotoxicity, nature reviews","volume":"4","author":"Kaplowitz","year":"2005","journal-title":"Drug Discov."},{"key":"10.1016\/j.cbi.2015.10.009_bib2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/03602532.2011.602688","article-title":"Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity","volume":"44","author":"Jaeschke","year":"2012","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.cbi.2015.10.009_bib3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3109\/03602532.2011.645579","article-title":"Role of immune reactions in drug-induced liver injury (DILI)","volume":"44","author":"Ju","year":"2012","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.cbi.2015.10.009_bib4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.cld.2013.07.002","article-title":"Mechanisms of drug-induced liver injury","volume":"17","author":"Yuan","year":"2013","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.cbi.2015.10.009_bib5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.tox.2014.05.007","article-title":"Sertraline induces endoplasmic reticulum stress in hepatic cells","volume":"322","author":"Chen","year":"2014","journal-title":"Toxicology"},{"key":"10.1016\/j.cbi.2015.10.009_bib6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cld.2007.06.001","article-title":"Mechanisms of drug-induced liver disease","volume":"11","author":"Gunawan","year":"2007","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.cbi.2015.10.009_bib7","doi-asserted-by":"crossref","first-page":"956","DOI":"10.2174\/138920009790711805","article-title":"Pharmacogenomics in drug induced liver injury","volume":"10","author":"Andrade","year":"2009","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.cbi.2015.10.009_bib8","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/hep.23720","article-title":"Pharmacogenetics of drug-induced liver injury","volume":"52","author":"Russmann","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cbi.2015.10.009_bib9","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1177\/0091270007312153","article-title":"New era in drug interaction evaluation: US food and drug administration update on CYP enzymes, transporters, and the guidance process","volume":"48","author":"Huang","year":"2008","journal-title":"J.\u00a0Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2015.10.009_bib10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0928-0987(01)00135-X","article-title":"Human hepatocyte culture systems for the in\u00a0vitro evaluation of cytochrome P450 expression and regulation","volume":"13","author":"LeCluyse","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.cbi.2015.10.009_bib11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/978-1-60761-688-7_15","article-title":"Evaluation of drug metabolism, drug-drug interactions, and in\u00a0vitro hepatotoxicity with cryopreserved human hepatocytes","volume":"640","author":"Li","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.cbi.2015.10.009_bib12","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00204-013-1078-5","article-title":"Recent advances in 2D and 3D in\u00a0vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME","volume":"87","author":"Godoy","year":"2013","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.cbi.2015.10.009_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/138920008783331086","article-title":"Cell lines: a tool for in\u00a0vitro drug metabolism studies","volume":"9","author":"Donato","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.cbi.2015.10.009_bib14","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1124\/dmd.110.035873","article-title":"Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes","volume":"39","author":"Guo","year":"2011","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"10.1016\/j.cbi.2015.10.009_bib15","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1124\/dmd.110.037259","article-title":"CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay","volume":"39","author":"Iwamura","year":"2011","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"10.1016\/j.cbi.2015.10.009_bib16","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bcp.2010.11.002","article-title":"The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells","volume":"81","author":"Zahno","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2015.10.009_bib17","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1124\/dmd.110.037077","article-title":"Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation","volume":"39","author":"Hosomi","year":"2011","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"10.1016\/j.cbi.2015.10.009_bib18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0887-2333(01)00011-X","article-title":"Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology","volume":"15","author":"Yoshitomi","year":"2001","journal-title":"Toxicol. vitro Int. J. Publ. Assoc. BIBRA"},{"key":"10.1016\/j.cbi.2015.10.009_bib19","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0076-6879(96)72044-X","article-title":"Use of human hepatocytes to study P450 gene induction","volume":"272","author":"Strom","year":"1996","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.cbi.2015.10.009_bib20","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.cbi.2015.10.009_bib21","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMra021844","article-title":"Drug-induced hepatotoxicity","volume":"349","author":"Lee","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cbi.2015.10.009_bib22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1081\/DMR-120034148","article-title":"Clinical perspectives on xenobiotic-induced hepatotoxicity","volume":"36","author":"Gunawan","year":"2004","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.cbi.2015.10.009_bib23","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1517\/17425255.4.11.1415","article-title":"Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science","volume":"4","author":"Antoine","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.cbi.2015.10.009_bib24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4161\/oxim.3.4.13246","article-title":"Deleterious effects of reactive metabolites","volume":"3","author":"Attia","year":"2010","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.cbi.2015.10.009_bib25","series-title":"Role of Reactive Metabolites in Drug-induced Hepatotoxicity, Handbook of Experimental Pharmacology","first-page":"165","author":"Srivastava","year":"2010"},{"key":"10.1016\/j.cbi.2015.10.009_bib26","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1023\/B:MCBI.0000038232.61760.9e","article-title":"Adenovirus mediated overexpression of CYP2E1 increases sensitivity of HepG2 cells to acetaminophen induced cytotoxicity","volume":"262","author":"Bai","year":"2004","journal-title":"Mol. Cell Biochem."},{"key":"10.1016\/j.cbi.2015.10.009_bib27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.tox.2005.08.003","article-title":"An in\u00a0vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics","volume":"216","author":"Vignati","year":"2005","journal-title":"Toxicology"},{"key":"10.1016\/j.cbi.2015.10.009_bib28","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.4161\/cbt.7.8.6283","article-title":"Overexpression of CYP2E1 enhances sensitivity of hepG2 cells to fas-mediated cytotoxicity","volume":"7","author":"Yan","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.cbi.2015.10.009_bib29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1126\/science.6248960","article-title":"Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen","volume":"209","author":"Knowles","year":"1980","journal-title":"Science"},{"key":"10.1016\/j.cbi.2015.10.009_bib30","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.pa.35.040195.002101","article-title":"Cytochromes P450 expression systems","volume":"35","author":"Gonzalez","year":"1995","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.cbi.2015.10.009_bib31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s12033-007-0010-8","article-title":"Gene delivery by lentivirus vectors","volume":"36","author":"Cockrell","year":"2007","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.cbi.2015.10.009_bib32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cbi.2008.03.015","article-title":"Preservation of hepatic phenotype in lentiviral-transduced primary human hepatocytes","volume":"173","author":"Zamule","year":"2008","journal-title":"Chemico-Biological Interact."},{"key":"10.1016\/j.cbi.2015.10.009_bib33","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s10616-013-9652-5","article-title":"Production, purification and titration of a lentivirus-based vector for gene delivery purposes","volume":"66","author":"Nasri","year":"2014","journal-title":"Cytotechnology"},{"key":"10.1016\/j.cbi.2015.10.009_bib34","doi-asserted-by":"crossref","first-page":"e51733","DOI":"10.1371\/journal.pone.0051733","article-title":"Generation of a genome scale lentiviral vector library for EF1alpha promoter-driven expression of human ORFs and identification of human genes affecting viral titer","volume":"7","author":"Skalamera","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cbi.2015.10.009_bib35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0022-3565(25)22836-1","article-title":"Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation","volume":"271","author":"Thummel","year":"1994","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cbi.2015.10.009_bib36","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","article-title":"Genetic contribution to variable human CYP3A-mediated metabolism","volume":"54","author":"Lamba","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.cbi.2015.10.009_bib37","doi-asserted-by":"crossref","first-page":"e60368","DOI":"10.1371\/journal.pone.0060368","article-title":"Gene expression variability in human hepatic drug metabolizing enzymes and transporters","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cbi.2015.10.009_bib38","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1021\/bi00457a031","article-title":"The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes","volume":"29","author":"Yamano","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2015.10.009_bib39","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cbi.2015.10.009_bib40","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1006\/abbi.2001.2499","article-title":"Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity","volume":"393","author":"Rodriguez-Antona","year":"2001","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.cbi.2015.10.009_bib41","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2174\/138920008785821710","article-title":"CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme","volume":"9","author":"Wang","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.cbi.2015.10.009_bib42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/dna.1998.17.231","article-title":"Quantification of multiple human cytochrome P450 mRNA molecules using competitive reverse transcriptase-PCR","volume":"17","author":"Andersen","year":"1998","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.cbi.2015.10.009_bib43","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1001\/jama.298.11.1312","article-title":"Prescribing amiodarone: an evidence-based review of clinical indications","volume":"298","author":"Vassallo","year":"2007","journal-title":"J.\u00a0Am. Med. Assoc."},{"key":"10.1016\/j.cbi.2015.10.009_bib44","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1517\/14740338.2012.660915","article-title":"Examining the safety of amiodarone","volume":"11","author":"Santangeli","year":"2012","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.cbi.2015.10.009_bib45","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.1840090504","article-title":"Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients","volume":"9","author":"Lewis","year":"1989","journal-title":"Hepatology"},{"key":"10.1016\/j.cbi.2015.10.009_bib46","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2174\/157016108784912019","article-title":"Amiodarone hepatotoxicity","volume":"6","author":"Babatin","year":"2008","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.cbi.2015.10.009_bib47","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/106002809502900605","article-title":"Fatal hepatotoxicity following oral administration of amiodarone","volume":"29","author":"Richer","year":"1995","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.cbi.2015.10.009_bib48","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.drudis.2011.05.007","article-title":"FDA-approved drug labeling for the study of drug-induced liver injury","volume":"16","author":"Chen","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.cbi.2015.10.009_bib49","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/clpt.1985.22","article-title":"Absolute bioavailability of amiodarone in normal subjects","volume":"37","author":"Pourbaix","year":"1985","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cbi.2015.10.009_bib50","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.2042-7158.1982.tb04692.x","article-title":"Identification and measurement of desethylamiodarone in blood plasma specimens from amiodarone-treated patients","volume":"34","author":"Flanagan","year":"1982","journal-title":"J.\u00a0Pharm. Pharmacol."},{"key":"10.1016\/j.cbi.2015.10.009_bib51","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1139\/y87-062","article-title":"Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues","volume":"65","author":"Brien","year":"1987","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.cbi.2015.10.009_bib52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3181\/00379727-190-42844","article-title":"Amiodarone and desethylamiodarone toxicity in isolated hepatocytes in culture, Proceedings of the Society for Experimental Biology and Medicine","volume":"190","author":"Gross","year":"1989","journal-title":"Soc. Exp. Biol. Med."},{"key":"10.1016\/j.cbi.2015.10.009_bib53","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1124\/jpet.106.108993","article-title":"Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives","volume":"319","author":"Waldhauser","year":"2006","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cbi.2015.10.009_bib54","article-title":"Hepatotoxicity during rapid intravenous loading with amiodarone: description of three cases and review of the literature","volume":"33","author":"Ratz Bravo","year":"2005","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.cbi.2015.10.009_bib55","first-page":"147","article-title":"The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole","volume":"11","author":"Elsherbiny","year":"2008","journal-title":"J.\u00a0Pharm. Pharm. Sci. Publ. Can. Soc. Pharm. Sci. Soc. Can. des Sci. Pharm."},{"key":"10.1016\/j.cbi.2015.10.009_bib56","series-title":"Metabolism of Amiodarone-biotransformation of Mono-N-Desethylamiodarone In-vitro, ETH Zurich, Switzerland","author":"Kozlik","year":"2003"},{"key":"10.1016\/j.cbi.2015.10.009_bib57","first-page":"271","article-title":"Identification and quantitation of novel metabolites of amiodarone in plasma of treated patients","volume":"24","author":"Ha","year":"2005","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"key":"10.1016\/j.cbi.2015.10.009_bib58","series-title":"WHO Model List of Essential Medicines","author":"WHO","year":"2013"},{"key":"10.1016\/j.cbi.2015.10.009_bib59","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/j.1875-9114.1997.tb03747.x","article-title":"A\u00a0review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom","volume":"17","author":"Garcia Rodriguez","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cbi.2015.10.009_bib60","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2125.2004.02133.x","article-title":"Acute and clinically relevant drug-induced liver injury: a population based case-control study","volume":"58","author":"de Abajo","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2015.10.009_bib61","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1365-2036.2007.03338.x","article-title":"Risk of acute liver injury associated with the use of drugs: a multicentre population survey","volume":"25","author":"Sabate","year":"2007","journal-title":"Alimentary Pharmacol. Ther."},{"key":"10.1016\/j.cbi.2015.10.009_bib62","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/BF00217059","article-title":"Cytotoxic effects of neuroleptic drugs","volume":"91","author":"Munyon","year":"1987","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.cbi.2015.10.009_bib63","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1139\/cjpp-2012-0223","article-title":"Molecular cytotoxic mechanisms of chlorpromazine in isolated rat hepatocytes","volume":"91","author":"MacAllister","year":"2013","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.cbi.2015.10.009_bib64","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1176\/ajp.133.6.646","article-title":"Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels","volume":"133","author":"Rivera-Calimlim","year":"1976","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.cbi.2015.10.009_bib65","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0021-9673(00)85556-9","article-title":"Thin-layer chromatography of chlorpromazine metabolites. Attempt to identify each of the metabolites appearing in blood, urine and feces of chronically medicated schizophrenics","volume":"75","author":"Turano","year":"1973","journal-title":"J.\u00a0Chromatogr."},{"key":"10.1016\/j.cbi.2015.10.009_bib66","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00007691-199402000-00004","article-title":"Important metabolites to measure in pharmacodynamic studies of chlorpromazine","volume":"16","author":"Chetty","year":"1994","journal-title":"Ther. drug Monit."},{"key":"10.1016\/j.cbi.2015.10.009_bib67","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0090-9556(25)08012-2","article-title":"Chlorpromazine metabolism in extracts of liver and small intestine from guinea pig and from man","volume":"11","author":"Hartmann","year":"1983","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"10.1016\/j.cbi.2015.10.009_bib68","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0090-9556(25)07406-9","article-title":"Stereo- and regioselective N- and S-oxidation of tertiary amines and sulfides in the presence of adult human liver microsomes","volume":"21","author":"Cashman","year":"1993","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"10.1016\/j.cbi.2015.10.009_bib69","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0024-3205(00)00613-5","article-title":"Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes","volume":"67","author":"Yoshii","year":"2000","journal-title":"Life Sci."},{"key":"10.1016\/j.cbi.2015.10.009_bib70","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.bcp.2010.06.045","article-title":"Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver\u2013A comparison with other phenothiazines","volume":"80","author":"Wojcikowski","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2015.10.009_bib71","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/hep.510290535","article-title":"Hepatotoxicity of psychotropic drugs","volume":"29","author":"Selim","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.cbi.2015.10.009_bib72","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0168-8278(88)80508-7","article-title":"A\u00a0proposed mechanism for chlorpromazine jaundice\u2013defective hepatic sulphoxidation combined with rapid hydroxylation","volume":"7","author":"Watson","year":"1988","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.cbi.2015.10.009_bib73","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3181\/00379727-155-39833","article-title":"Adverse effects of chlorpromazine metabolites on isolated hepatocytes","volume":"155","author":"Abernathy","year":"1977","journal-title":"Proc. Soc. Exp. Biol. Med. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.cbi.2015.10.009_bib74","doi-asserted-by":"crossref","first-page":"402","DOI":"10.4269\/ajtmh.2006.75.402","article-title":"Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I","volume":"75","author":"Hill","year":"2006","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.cbi.2015.10.009_bib75","first-page":"30","article-title":"The hemolytic effect of primaquine. V. Primaquine sensitivity as a manifestation of a multiple drug sensitivity","volume":"45","author":"Dern","year":"1955","journal-title":"J.\u00a0Lab. Clin. Med."},{"key":"10.1016\/j.cbi.2015.10.009_bib76","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/1475-2875-11-280","article-title":"Primaquine radical cure of Plasmodium vivax: a critical review of the literature","volume":"11","author":"John","year":"2012","journal-title":"Malar. J."},{"key":"10.1016\/j.cbi.2015.10.009_bib77","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1128\/AAC.32.6.793","article-title":"Antimalarial agents: mechanisms of action","volume":"32","author":"Schlesinger","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cbi.2015.10.009_bib78","doi-asserted-by":"crossref","first-page":"6848","DOI":"10.1016\/S0021-9258(19)50504-X","article-title":"Hydroxylated metabolites of the antimalarial drug primaquine. Oxidation and redox cycling","volume":"267","author":"Vasquez-Vivar","year":"1992","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.cbi.2015.10.009_bib79","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2125.1985.tb02709.x","article-title":"Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size","volume":"19","author":"Mihaly","year":"1985","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2015.10.009_bib80","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2125.1984.tb02369.x","article-title":"Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite","volume":"17","author":"Mihaly","year":"1984","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2015.10.009_bib81","doi-asserted-by":"crossref","first-page":"532","DOI":"10.4269\/ajtmh.1990.42.532","article-title":"In\u00a0vitro effects of primaquine and primaquine metabolites on exoerythrocytic stages of Plasmodium berghei","volume":"42","author":"Bates","year":"1990","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.cbi.2015.10.009_bib82","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0041-008X(85)90155-3","article-title":"Structure-activity relationships of putative primaquine metabolites causing methemoglobin formation in canine hemolysates","volume":"81","author":"Link","year":"1985","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.cbi.2015.10.009_bib83","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1021\/jm00402a001","article-title":"Oxidants, oxidant drugs, and malaria","volume":"31","author":"Vennerstrom","year":"1988","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.cbi.2015.10.009_bib84","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1016\/0006-2952(88)90263-8","article-title":"Studies on the mechanisms of oxidation in the erythrocyte by metabolites of primaquine","volume":"37","author":"Fletcher","year":"1988","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2015.10.009_bib85","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1124\/jpet.103.062984","article-title":"Primaquine-induced hemolytic anemia: susceptibility of normal versus glutathione-depleted rat erythrocytes to 5-hydroxyprimaquine","volume":"309","author":"Bowman","year":"2004","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cbi.2015.10.009_bib86","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1124\/jpet.105.086488","article-title":"Primaquine-induced hemolytic anemia: role of membrane lipid peroxidation and cytoskeletal protein alterations in the hemotoxicity of 5-hydroxyprimaquine","volume":"314","author":"Bowman","year":"2005","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cbi.2015.10.009_bib87","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.taap.2009.07.012","article-title":"Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes","volume":"241","author":"Ganesan","year":"2009","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.cbi.2015.10.009_bib88","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/1475-2875-11-259","article-title":"CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine","volume":"11","author":"Pybus","year":"2012","journal-title":"Malar. J."},{"key":"10.1016\/j.cbi.2015.10.009_bib89","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/1475-2875-12-212","article-title":"The metabolism of primaquine to its active metabolite is dependent on CYP 2D6","volume":"12","author":"Pybus","year":"2013","journal-title":"Malar. J."},{"key":"10.1016\/j.cbi.2015.10.009_bib90","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1056\/NEJMc1301936","article-title":"Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria","volume":"369","author":"Bennett","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cbi.2015.10.009_bib91","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.cbi.2015.10.009_bib92","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0006-2952(98)00304-9","article-title":"Cytochrome 1A1 induction by primaquine in human hepatocytes and HepG2 cells: absence of binding to the aryl hydrocarbon receptor","volume":"57","author":"Fontaine","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2015.10.009_bib93","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0022-3565(24)29529-X","article-title":"Transcriptional and post-translational regulation of CYP1A1 by primaquine","volume":"297","author":"Werlinder","year":"2001","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cbi.2015.10.009_bib94","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00228-002-0512-z","article-title":"Cytochrome P450 1A1\/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells","volume":"58","author":"Bapiro","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279715300880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279715300880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T19:45:34Z","timestamp":1762112734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279715300880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":94,"alternative-id":["S0009279715300880"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2015.10.009","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2015.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}